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A 71-year-old man was admitted with a 2-month history of back pain, weakness, and dyspnea. Medical history 
reports immunoglobulin A nephropathy resulting in renal 
transplantation at the age of 47. He redeveloped severe chronic 
renal insufficiency based on allograft rejection, with a current 
Cockroft–Gault creatinine clearance of 24 ml/min and second-
ary hyperparathyroidism.
Positron emission tomography–computed tomography 
scan shows a 25-mm tumor of the left upper lobe, malignant 
mediastinal lymph nodes, and extensive bone metastases 
(Fig. 1). Pathologic finding reports epidermal growth factor 
receptor wild-type nonsquamous non–small-cell lung cancer 
on peripheral bronchoscopic biopsy. Chronic renal impair-
ment impedes use of chemotherapy. Denosumab 120 mg was 
administered subcutaneously for diffuse bone disease, along 
with calcium 1000 mg and vitamin D 800 I.U. per day. In the 
following days, several biochemical aberrations suggesting 
tumor lysis syndrome (TLS) were noted (Fig. 2). The patient 
required treatment with intravenous hydration, urine alkaliza-
tion, and supplemental calcium. After a critical period, bio-
chemical disorders resolved to baseline levels. The patient 
was discharged on best supportive care 2 weeks later.
DISCUSSION
TLS is a potentially fatal complication at the start of chemo-
therapy for bulky solid tumors.1 Risk factors are chronic renal 
impairment, high serum levels of lactate dehydrogenase or 
uric acid, and dehydration.
The time course of the biological tests is in line with the 
criteria for definition of laboratory TLS in a recent review.2 
Only the time course of creatinine is less typical, probably 
explained by nephrotoxic medication in the recent past. 
Consequently, we considered TLS caused by denosumab in our 
patient, to our knowledge, a hitherto undescribed condition.
Bone-targeted therapy with the human monoclonal 
antibody denosumab is of proven value to reduce the risk of 
skeletal-related events in patients with solid tumors with bone 
metastases. The mode of action is inhibition of the receptor 
activator of nuclear factor kappa-B ligand (RANKL) respon-
sible for formation, function, and survival of the osteoclast.
Whether denosumab also has direct antitumor effects is 
unclear. RANKL expression has been documented in several 
cancer cell lines.3 The role of RANKL in tumor migration and 
invasion in lung cancer is being examined. In mice, RANKL 
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inhibition blocks lung cancer–induced osteolytic lesions and 
reduces skeletal-related events not only in RANK-expressing 
but also in RANK-negative lung cancers.4 Exploratory data 
from a phase III clinical trial reported a possible delay of 
tumor progression and improvement of overall survival by 
RANKL inhibition: patients with non–small-cell lung can-
cer receiving denosumab had a median overall survival of 9.5 
months versus 8.0 months for zoledronic acid (hazard ratio: 
0.78; p = 0.0104).5
Our patient had severe impairment of renal function 
(clearance 24 ml/min). In general, administration of deno-
sumab does not require renal function monitoring because it 
does not depend on renal clearance for metabolism or excre-
tion. Nevertheless, in all phase III studies, the use of deno-
sumab 120 mg subcutaneously was limited to patients with a 
creatinine clearance of more than 30 ml/min. In a recent study, 
no significant difference in toxicity profile according to renal 
impairment and no TLS were reported.6
This case report raises several unanswered questions: 
can denosumab act on tumor cells and cause TLS? Is this more 
likely in case of severe impairment of renal function? Until 
these questions are solved, we suggest caution using deno-
sumab in patients with severe renal impairment and diffuse 
bone metastases.
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FIGURE 2.  Time course of lactate dehydrogenase (LDH), 
potassium, calcium, phosphorus, creatinine, and uric acid. 
Day 1 = administration of denosumab.
